544 related articles for article (PubMed ID: 25491492)
1. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
2. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
3. [Tocilizumab in rheumatoid arthritis].
Rueda Gotor J; Blanco Alonso R
Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
Navarro-Millán I; Singh JA; Curtis JR
Clin Ther; 2012 Apr; 34(4):788-802.e3. PubMed ID: 22444783
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
6. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
Ogata A; Kato Y; Higa S; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):258-267. PubMed ID: 30427250
[TBL] [Abstract][Full Text] [Related]
7. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
Woodrick RS; Ruderman EM
Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
Navarro G; Taroumian S; Barroso N; Duan L; Furst D
Semin Arthritis Rheum; 2014 Feb; 43(4):458-69. PubMed ID: 24262929
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
11. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in the treatment of rheumatoid arthritis and beyond.
Shetty A; Hanson R; Korsten P; Shawagfeh M; Arami S; Volkov S; Vila O; Swedler W; Shunaigat AN; Smadi S; Sawaqed R; Perkins D; Shahrara S; Sweiss NJ
Drug Des Devel Ther; 2014; 8():349-64. PubMed ID: 24729685
[TBL] [Abstract][Full Text] [Related]
14. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.
Miyagawa I; Nakayamada S; Saito K; Hanami K; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
Mod Rheumatol; 2014 May; 24(3):405-9. PubMed ID: 24252016
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
16. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
Kim GW; Lee NR; Pi RH; Lim YS; Lee YM; Lee JM; Jeong HS; Chung SH
Arch Pharm Res; 2015; 38(5):575-84. PubMed ID: 25648633
[TBL] [Abstract][Full Text] [Related]
17. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
[TBL] [Abstract][Full Text] [Related]
18. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
19. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.
Semerano L; Thiolat A; Minichiello E; Clavel G; Bessis N; Boissier MC
Expert Opin Investig Drugs; 2014 Jul; 23(7):979-99. PubMed ID: 24766460
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]